NL-OMON39063尚未招募不适用
ONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY) - Response to interferon in hepatitis B: relation to IL28b and Apo E
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •chronic hepatitis B
- •treated with interferon
排除标准
- •coinfections with HIV, HCV
研究者
相似试验
招募中
不适用
ong-term follow-up of patients with extrahepatic biliary atresie and Kasai hepatoportoenterostomy: assessment of abnormalities on MR imaging and implications for follow-up.Kasai portoenterostomy10019654congenital biliary atresiaNL-OMON30396Erasmus MC, Universitair Medisch Centrum Rotterdam16
尚未招募
2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis BACTRN12614000628640Gilead Sciences, Inc.150
进行中（未招募）
1 期
Study to evaluate long term effect of an experimental approach of gene therapy to treat ß-thalassemia major, know also as transfusion dependent ß-thalassemia, and the sickle cell disease.Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-ITBLUEBIRD BIO, INC.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-GBbluebird bio, Inc.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-DEbluebird bio, Inc.94